gpr183a Antibody

What is GPR183 and why is it important in immunological research?

GPR183 (also known as Epstein-Barr virus-induced G protein-coupled receptor 2 or EBI2) is a G protein-coupled receptor that mediates migration and positioning of immune cells during T cell-dependent antibody responses. It plays critical roles in:

• B lymphocyte migration and positioning in secondary lymphoid organs

• T cell trafficking and immune surveillance

• Macrophage recruitment to sites of inflammation

• Lymphoid tissue development and organization

GPR183 has emerged as a significant research target due to its altered expression in autoimmune conditions like systemic lupus erythematosus (SLE), infectious diseases including tuberculosis, and respiratory infections such as influenza . Research indicates GPR183 functions as a receptor for oxysterols, particularly 7α,25-dihydroxycholesterol, which creates chemotactic gradients directing immune cell movement.

What criteria should I consider when selecting a GPR183 antibody for my research?

When selecting a GPR183 antibody, researchers should evaluate multiple parameters:

• Antibody format: Determine whether polyclonal or monoclonal antibodies better suit your application. Polyclonals recognize multiple epitopes and may provide stronger signals, while monoclonals offer higher specificity.

• Target species reactivity: Verify cross-reactivity if working with non-human models. Current literature shows extensive use in human and mouse models .

• Application validation: Confirm the antibody has been validated for your specific application (WB, IHC, flow cytometry, etc.).

• Recognition domain: Consider whether the antibody targets the N-terminus, C-terminus, or an internal domain. For instance, some antibodies target the distal end of the carboxyl-terminal tail of human GPR183 .

• Phosphorylation state sensitivity: Some antibodies detect only non-phosphorylated forms of GPR183 .

For immunohistochemistry applications in particular, IHC-grade GPR183 antibodies have been validated and optimized for tissue section analysis .

How should I optimize GPR183 antibody protocols for flow cytometry to assess expression in lymphocyte subsets?

Optimizing GPR183 antibody protocols for flow cytometry requires attention to several technical aspects:

Protocol optimization steps:

• Sample preparation: Fresh or properly cryopreserved samples yield superior results. Research indicates that improper freezing can affect GPR183 expression levels .

• Appropriate controls: Include FMO (fluorescence minus one) controls, particularly important given the variable expression of GPR183 across lymphocyte subsets.

• Titration: Determine optimal antibody concentration through titration experiments (typically 0.1-5 μg/ml range).

• Buffer selection: Use buffers with protein blockers to reduce non-specific binding.

• Multiparameter panel design: When designing panels to assess GPR183 alongside other markers, consider fluorochrome brightness and spectral overlap.

Validated panel example:
As demonstrated in recent research, combining GPR183 with other lineage markers (CD19, CD20, CD27, CD38, IgD) and activation markers (CD25, CD69, CD71, CD80, CD86) enables comprehensive assessment of GPR183 expression across B cell subpopulations .

For identifying atypical/age-associated B cells (ABCs) with altered GPR183 expression, include markers such as CD11c, T-bet, CD85j, Fcrl4, Fcrl5, CXCR3, and CXCR5 .

What methods are most effective for validating GPR183 antibody specificity?

Validating GPR183 antibody specificity requires a multi-faceted approach:

• Genetic validation: Compare antibody staining between wild-type and GPR183 knockout models or GPR183-depleted cell lines. Research demonstrates that GPR183 knockout models are valuable tools for verifying antibody specificity .

• Peptide competition: Pre-incubation with the immunizing peptide should abolish specific staining.

• Recombinant protein controls: Overexpression systems provide positive controls for specificity testing.

• Multiple antibody validation: Use antibodies recognizing different epitopes of GPR183 to confirm staining patterns.

• Correlation with mRNA expression: Compare protein detection with mRNA expression levels using qPCR or RNA-seq data. Studies show concordance between GPR183 protein and mRNA expression changes in disease states .

A rigorous validation protocol should include at least three of these methods, with genetic validation considered the gold standard when feasible.

How can GPR183 antibodies be utilized to investigate the role of this receptor in oxysterol-mediated immune cell migration?

GPR183 antibodies can be applied in several sophisticated experimental approaches to study oxysterol-mediated immune cell migration:

• In vitro migration assays: Utilize GPR183 antibodies in chemotaxis assays to:

  • Block receptor function and assess migration toward synthetic or endogenous oxysterols

  • Compare migration between wild-type and GPR183-knockout or depleted cells

  • Evaluate F-actin polymerization as a downstream indicator of migration signaling

• Live cell imaging: Use fluorescently-labeled GPR183 antibodies that don't block function to track receptor distribution during migration.

• 3D spheroid models: Recent research demonstrates the application of GPR183 antibodies in 3D spheroid co-culture systems to assess macrophage infiltration into tumor spheroids, allowing visualization of dynamic cell-cell interactions .

• In vivo migration studies: Combine GPR183 antibodies with adoptive transfer models to track the migration of specific immune cell populations.

Research findings demonstrate that genetic depletion and pharmacological inhibition of GPR183 impair macrophage movement in both 2D and 3D environments, confirming the receptor's role in directing immune cell migration through oxysterol gradients .

What experimental design considerations are crucial when using GPR183 antibodies to investigate its role in autoimmune diseases?

When investigating GPR183 in autoimmune contexts, several critical experimental design factors must be considered:

• Patient stratification: GPR183 expression correlates with disease activity in SLE, making proper stratification of patient samples essential. Group patients based on:

  • Disease activity scores (e.g., SLEDAI for SLE)

  • Treatment status

  • Disease duration

  • Comorbidities

• Appropriate controls: Include both healthy controls and disease controls (other autoimmune conditions) to distinguish GPR183-specific effects.

• Cell subset analysis: GPR183 expression varies significantly between lymphocyte subpopulations. Research shows differential expression patterns in:

  • Naïve vs. memory B cells

  • CD27-IgD+ B cells (potential biomarker for SLE disease activity)

  • Atypical/age-associated B cells (ABCs)

  • Various T cell subsets

• Functional correlation: Correlate GPR183 expression with functional readouts, such as:

  • Complement protein levels (C3, C4, C1q)

  • Autoantibody titers

  • Cytokine production profiles

  • Migration capacity in response to oxysterols

• Stimulation experiments: Consider type I interferon stimulation experiments, as research indicates that IFN can down-regulate GPR183 expression in peripheral blood T and B cell subsets .

Table 1: GPR183 expression patterns in lymphocyte subsets and their correlation with SLE disease activity based on current research findings .

How should researchers interpret contradictory GPR183 expression data between tissue and circulation in disease models?

Interpreting seemingly contradictory GPR183 expression patterns between tissue and circulation requires careful analysis:

• Consider dynamic trafficking: Lower GPR183 expression in blood may reflect enhanced migration of GPR183-expressing cells to affected tissues. Studies demonstrate increased GPR183 expression in lungs during Mycobacterium tuberculosis infection with concurrent decreased expression in blood .

• Analyze expression kinetics: Temporal analysis is crucial as GPR183 expression follows dynamic patterns during disease progression:

  • Early phase: Increased oxysterol production in tissues drives GPR183-dependent recruitment

  • Late phase: Potential receptor downregulation after prolonged stimulation

• Evaluate local microenvironment effects: Local cytokine milieu significantly impacts GPR183 expression. Research shows that:

  • Type I interferons downregulate GPR183 expression in lymphocytes

  • Inflammatory stimuli upregulate oxysterol-producing enzymes (CH25H, CYP7B1) in tissue macrophages

• Consider cell-specific regulation: Different immune cell subsets may regulate GPR183 expression differently in response to the same stimuli.

• Tissue-specific analysis: When possible, perform concurrent analysis of matched blood and tissue samples from the same subjects.

Table 2: Comparison of GPR183 expression patterns between circulation and tissue in infection and autoimmune models based on research findings .

What are the critical technical considerations when using GPR183 antibodies in multi-parameter spectral flow cytometry panels?

Incorporating GPR183 antibodies into multi-parameter spectral flow cytometry requires addressing several technical challenges:

• Panel design considerations:

  • Fluorochrome selection: Choose a bright fluorochrome for GPR183 detection since expression levels can be variable across cell populations

  • Spectral overlap: Position the GPR183 fluorochrome to minimize spillover with markers of similar expression patterns

  • Panel balance: Distribute bright and dim fluorochromes across markers of varying expression levels

• Antibody titration: Critical for spectral flow cytometry to minimize background and optimize signal-to-noise ratio. Recent research utilizing 36-color spectral flow cytometry panels for ABC cell characterization highlights the importance of optimized titration .

• Controls for spectral unmixing:

  • Include all single-stained controls for proper spectral unmixing

  • Consider fluorescence minus one (FMO) controls for GPR183 to establish accurate gating

  • Use GPR183-knockout or depleted cells as biological negative controls when available

• Staining protocol optimization:

  • Buffer composition affects antibody binding efficiency

  • Fixation/permeabilization may be needed for detecting intracellular GPR183 pools

  • Staining temperature and duration require optimization (typically 30 minutes at 4°C)

• Sample preparation considerations:

  • Ensure proper Fc receptor blocking to reduce non-specific binding

  • Maintain consistent sample processing times to avoid variability in surface marker expression

  • Consider the impact of cell isolation methods on GPR183 expression levels

Research demonstrates that optimized 36-color spectral flow cytometry panels can reliably assess GPR183 expression alongside other markers on both fresh and cryopreserved human peripheral blood samples .

How can GPR183 antibodies be applied to investigate the receptor's role in infectious disease models beyond established applications?

GPR183 antibodies can be deployed in novel ways to explore the receptor's roles in infectious disease progression:

• Dual immunofluorescence approaches: Combine GPR183 antibodies with pathogen-specific staining to visualize receptor expression in relation to infected cells. Research using this approach has revealed the role of GPR183 in macrophage recruitment during Mycobacterium tuberculosis and influenza infections .

• Sequential tissue analysis: Use GPR183 antibodies on serial tissue sections to track temporal changes in receptor expression during different stages of infection.

• Single-cell analysis platforms: Integrate GPR183 antibodies into mass cytometry or single-cell RNA-seq workflows to correlate protein expression with transcriptional changes at the single-cell level.

• GPR183 antagonist studies: Combine GPR183 antibodies with receptor antagonists (such as NIBR189) to:

  • Investigate therapeutic potential in excessive inflammation

  • Distinguish receptor-dependent and independent processes

  • Assess effects on pathogen clearance versus immunopathology

• Cross-species comparative studies: Apply GPR183 antibodies across different infection models to identify conserved versus pathogen-specific responses.

Recent research demonstrates that GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection models, highlighting a potentially broader role for GPR183 in respiratory infections beyond previously studied pathogens .

What technical challenges must be addressed when developing quantitative assays to correlate GPR183 expression levels with disease activity?

Developing robust quantitative assays for correlating GPR183 expression with disease activity presents several technical challenges:

• Standardization issues:

  • Absolute quantification requires calibrated reference standards

  • Different antibody clones yield different signal intensities

  • Various detection platforms have different dynamic ranges and sensitivities

• Pre-analytical variables affecting GPR183 measurement:

  • Sample collection method and timing

  • Processing delays affect receptor expression

  • Anticoagulant choice impacts staining patterns

  • Freeze-thaw cycles degrade surface epitopes

• Normalization approaches:

  • Internal calibrators should be included in each assay run

  • Consider ratio to housekeeping proteins rather than absolute values

  • Use quantitative flow cytometry with calibration beads to calculate molecules of equivalent soluble fluorochrome (MESF)

• Statistical considerations for biomarker development:

  • Receiver operating characteristic (ROC) curve analysis for determining diagnostic value

  • Multivariate analysis to assess independent predictive value

  • Correlation with established disease activity markers

Research has demonstrated that GPR183 expression in CD27-IgD+ B cells may have value in distinguishing between inactive and active SLE patients, with ROC curve analysis supporting its potential as a biomarker .

Table 3: Comparison of quantitative techniques for GPR183 measurement with their respective advantages, limitations, and quantification approaches.

What are the emerging applications of GPR183 antibodies in therapeutic development research?

Future applications of GPR183 antibodies in therapeutic research include:

• Biomarker development: Standardized GPR183 detection for stratifying patients in clinical trials for autoimmune diseases, particularly SLE where expression correlates with disease activity .

• Therapeutic response monitoring: Using GPR183 expression changes to track efficacy of experimental therapies targeting the oxysterol-GPR183 axis.

• Novel therapeutic target validation: GPR183 antibodies in blocking studies to validate the receptor as a drug target for conditions characterized by dysregulated immune cell migration.

• Companion diagnostic development: GPR183 expression profiling may identify patients most likely to respond to therapies targeting this pathway.

• In vivo imaging: Development of imaging tracers based on GPR183 antibodies to visualize immune cell trafficking non-invasively.

Research indicates that GPR183 expression levels may serve as a biomarker for the activity of therapeutic combinations containing CD47-targeted therapy in B-cell lymphomas, suggesting broader applications in cancer immunotherapy response prediction .

GPR183 Antibody Research: Comprehensive Report

GPR183 Antibody in Scientific Research: Comprehensive FAQ Guide

What is GPR183 and why is it important in immunological research?

GPR183 (also known as Epstein-Barr virus-induced G protein-coupled receptor 2 or EBI2) is a G protein-coupled receptor that mediates migration and positioning of immune cells during T cell-dependent antibody responses. It plays critical roles in:

• B lymphocyte migration and positioning in secondary lymphoid organs

• T cell trafficking and immune surveillance

• Macrophage recruitment to sites of inflammation

• Lymphoid tissue development and organization

GPR183 has emerged as a significant research target due to its altered expression in autoimmune conditions like systemic lupus erythematosus (SLE), infectious diseases including tuberculosis, and respiratory infections such as influenza . Research indicates GPR183 functions as a receptor for oxysterols, particularly 7α,25-dihydroxycholesterol, which creates chemotactic gradients directing immune cell movement.

What criteria should I consider when selecting a GPR183 antibody for my research?

When selecting a GPR183 antibody, researchers should evaluate multiple parameters:

• Antibody format: Determine whether polyclonal or monoclonal antibodies better suit your application. Polyclonals recognize multiple epitopes and may provide stronger signals, while monoclonals offer higher specificity.

• Target species reactivity: Verify cross-reactivity if working with non-human models. Current literature shows extensive use in human and mouse models .

• Application validation: Confirm the antibody has been validated for your specific application (WB, IHC, flow cytometry, etc.).

• Recognition domain: Consider whether the antibody targets the N-terminus, C-terminus, or an internal domain. For instance, some antibodies target the distal end of the carboxyl-terminal tail of human GPR183 .

• Phosphorylation state sensitivity: Some antibodies detect only non-phosphorylated forms of GPR183 .

For immunohistochemistry applications in particular, IHC-grade GPR183 antibodies have been validated and optimized for tissue section analysis .

How should I optimize GPR183 antibody protocols for flow cytometry to assess expression in lymphocyte subsets?

Optimizing GPR183 antibody protocols for flow cytometry requires attention to several technical aspects:

Protocol optimization steps:

• Sample preparation: Fresh or properly cryopreserved samples yield superior results. Research indicates that improper freezing can affect GPR183 expression levels .

• Appropriate controls: Include FMO (fluorescence minus one) controls, particularly important given the variable expression of GPR183 across lymphocyte subsets.

• Titration: Determine optimal antibody concentration through titration experiments (typically 0.1-5 μg/ml range).

• Buffer selection: Use buffers with protein blockers to reduce non-specific binding.

• Multiparameter panel design: When designing panels to assess GPR183 alongside other markers, consider fluorochrome brightness and spectral overlap.

Validated panel example:
As demonstrated in recent research, combining GPR183 with other lineage markers (CD19, CD20, CD27, CD38, IgD) and activation markers (CD25, CD69, CD71, CD80, CD86) enables comprehensive assessment of GPR183 expression across B cell subpopulations .

For identifying atypical/age-associated B cells (ABCs) with altered GPR183 expression, include markers such as CD11c, T-bet, CD85j, Fcrl4, Fcrl5, CXCR3, and CXCR5 .

What methods are most effective for validating GPR183 antibody specificity?

Validating GPR183 antibody specificity requires a multi-faceted approach:

• Genetic validation: Compare antibody staining between wild-type and GPR183 knockout models or GPR183-depleted cell lines. Research demonstrates that GPR183 knockout models are valuable tools for verifying antibody specificity .

• Peptide competition: Pre-incubation with the immunizing peptide should abolish specific staining.

• Recombinant protein controls: Overexpression systems provide positive controls for specificity testing.

• Multiple antibody validation: Use antibodies recognizing different epitopes of GPR183 to confirm staining patterns.

• Correlation with mRNA expression: Compare protein detection with mRNA expression levels using qPCR or RNA-seq data. Studies show concordance between GPR183 protein and mRNA expression changes in disease states .

A rigorous validation protocol should include at least three of these methods, with genetic validation considered the gold standard when feasible.

How can GPR183 antibodies be utilized to investigate the role of this receptor in oxysterol-mediated immune cell migration?

GPR183 antibodies can be applied in several sophisticated experimental approaches to study oxysterol-mediated immune cell migration:

• In vitro migration assays: Utilize GPR183 antibodies in chemotaxis assays to:

  • Block receptor function and assess migration toward synthetic or endogenous oxysterols

  • Compare migration between wild-type and GPR183-knockout or depleted cells

  • Evaluate F-actin polymerization as a downstream indicator of migration signaling

• Live cell imaging: Use fluorescently-labeled GPR183 antibodies that don't block function to track receptor distribution during migration.

• 3D spheroid models: Recent research demonstrates the application of GPR183 antibodies in 3D spheroid co-culture systems to assess macrophage infiltration into tumor spheroids, allowing visualization of dynamic cell-cell interactions .

• In vivo migration studies: Combine GPR183 antibodies with adoptive transfer models to track the migration of specific immune cell populations.

Research findings demonstrate that genetic depletion and pharmacological inhibition of GPR183 impair macrophage movement in both 2D and 3D environments, confirming the receptor's role in directing immune cell migration through oxysterol gradients .

What experimental design considerations are crucial when using GPR183 antibodies to investigate its role in autoimmune diseases?

When investigating GPR183 in autoimmune contexts, several critical experimental design factors must be considered:

• Patient stratification: GPR183 expression correlates with disease activity in SLE, making proper stratification of patient samples essential. Group patients based on:

  • Disease activity scores (e.g., SLEDAI for SLE)

  • Treatment status

  • Disease duration

  • Comorbidities

• Appropriate controls: Include both healthy controls and disease controls (other autoimmune conditions) to distinguish GPR183-specific effects.

• Cell subset analysis: GPR183 expression varies significantly between lymphocyte subpopulations. Research shows differential expression patterns in:

  • Naïve vs. memory B cells

  • CD27-IgD+ B cells (potential biomarker for SLE disease activity)

  • Atypical/age-associated B cells (ABCs)

  • Various T cell subsets

• Functional correlation: Correlate GPR183 expression with functional readouts, such as:

  • Complement protein levels (C3, C4, C1q)

  • Autoantibody titers

  • Cytokine production profiles

  • Migration capacity in response to oxysterols

• Stimulation experiments: Consider type I interferon stimulation experiments, as research indicates that IFN can down-regulate GPR183 expression in peripheral blood T and B cell subsets .

Table 1: GPR183 expression patterns in lymphocyte subsets and their correlation with SLE disease activity based on current research findings .

How should researchers interpret contradictory GPR183 expression data between tissue and circulation in disease models?

Interpreting seemingly contradictory GPR183 expression patterns between tissue and circulation requires careful analysis:

• Consider dynamic trafficking: Lower GPR183 expression in blood may reflect enhanced migration of GPR183-expressing cells to affected tissues. Studies demonstrate increased GPR183 expression in lungs during Mycobacterium tuberculosis infection with concurrent decreased expression in blood .

• Analyze expression kinetics: Temporal analysis is crucial as GPR183 expression follows dynamic patterns during disease progression:

  • Early phase: Increased oxysterol production in tissues drives GPR183-dependent recruitment

  • Late phase: Potential receptor downregulation after prolonged stimulation

• Evaluate local microenvironment effects: Local cytokine milieu significantly impacts GPR183 expression. Research shows that:

  • Type I interferons downregulate GPR183 expression in lymphocytes

  • Inflammatory stimuli upregulate oxysterol-producing enzymes (CH25H, CYP7B1) in tissue macrophages

• Consider cell-specific regulation: Different immune cell subsets may regulate GPR183 expression differently in response to the same stimuli.

• Tissue-specific analysis: When possible, perform concurrent analysis of matched blood and tissue samples from the same subjects.

Table 2: Comparison of GPR183 expression patterns between circulation and tissue in infection and autoimmune models based on research findings .

What are the critical technical considerations when using GPR183 antibodies in multi-parameter spectral flow cytometry panels?

Incorporating GPR183 antibodies into multi-parameter spectral flow cytometry requires addressing several technical challenges:

• Panel design considerations:

  • Fluorochrome selection: Choose a bright fluorochrome for GPR183 detection since expression levels can be variable across cell populations

  • Spectral overlap: Position the GPR183 fluorochrome to minimize spillover with markers of similar expression patterns

  • Panel balance: Distribute bright and dim fluorochromes across markers of varying expression levels

• Antibody titration: Critical for spectral flow cytometry to minimize background and optimize signal-to-noise ratio. Recent research utilizing 36-color spectral flow cytometry panels for ABC cell characterization highlights the importance of optimized titration .

• Controls for spectral unmixing:

  • Include all single-stained controls for proper spectral unmixing

  • Consider fluorescence minus one (FMO) controls for GPR183 to establish accurate gating

  • Use GPR183-knockout or depleted cells as biological negative controls when available

• Staining protocol optimization:

  • Buffer composition affects antibody binding efficiency

  • Fixation/permeabilization may be needed for detecting intracellular GPR183 pools

  • Staining temperature and duration require optimization (typically 30 minutes at 4°C)

• Sample preparation considerations:

  • Ensure proper Fc receptor blocking to reduce non-specific binding

  • Maintain consistent sample processing times to avoid variability in surface marker expression

  • Consider the impact of cell isolation methods on GPR183 expression levels

Research demonstrates that optimized 36-color spectral flow cytometry panels can reliably assess GPR183 expression alongside other markers on both fresh and cryopreserved human peripheral blood samples .

How can GPR183 antibodies be applied to investigate the receptor's role in infectious disease models beyond established applications?

GPR183 antibodies can be deployed in novel ways to explore the receptor's roles in infectious disease progression:

• Dual immunofluorescence approaches: Combine GPR183 antibodies with pathogen-specific staining to visualize receptor expression in relation to infected cells. Research using this approach has revealed the role of GPR183 in macrophage recruitment during Mycobacterium tuberculosis and influenza infections .

• Sequential tissue analysis: Use GPR183 antibodies on serial tissue sections to track temporal changes in receptor expression during different stages of infection.

• Single-cell analysis platforms: Integrate GPR183 antibodies into mass cytometry or single-cell RNA-seq workflows to correlate protein expression with transcriptional changes at the single-cell level.

• GPR183 antagonist studies: Combine GPR183 antibodies with receptor antagonists (such as NIBR189) to:

  • Investigate therapeutic potential in excessive inflammation

  • Distinguish receptor-dependent and independent processes

  • Assess effects on pathogen clearance versus immunopathology

• Cross-species comparative studies: Apply GPR183 antibodies across different infection models to identify conserved versus pathogen-specific responses.

Recent research demonstrates that GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection models, highlighting a potentially broader role for GPR183 in respiratory infections beyond previously studied pathogens .

What technical challenges must be addressed when developing quantitative assays to correlate GPR183 expression levels with disease activity?

Developing robust quantitative assays for correlating GPR183 expression with disease activity presents several technical challenges:

• Standardization issues:

  • Absolute quantification requires calibrated reference standards

  • Different antibody clones yield different signal intensities

  • Various detection platforms have different dynamic ranges and sensitivities

• Pre-analytical variables affecting GPR183 measurement:

  • Sample collection method and timing

  • Processing delays affect receptor expression

  • Anticoagulant choice impacts staining patterns

  • Freeze-thaw cycles degrade surface epitopes

• Normalization approaches:

  • Internal calibrators should be included in each assay run

  • Consider ratio to housekeeping proteins rather than absolute values

  • Use quantitative flow cytometry with calibration beads to calculate molecules of equivalent soluble fluorochrome (MESF)

• Statistical considerations for biomarker development:

  • Receiver operating characteristic (ROC) curve analysis for determining diagnostic value

  • Multivariate analysis to assess independent predictive value

  • Correlation with established disease activity markers

Research has demonstrated that GPR183 expression in CD27-IgD+ B cells may have value in distinguishing between inactive and active SLE patients, with ROC curve analysis supporting its potential as a biomarker .

Table 3: Comparison of quantitative techniques for GPR183 measurement with their respective advantages, limitations, and quantification approaches.

What are the emerging applications of GPR183 antibodies in therapeutic development research?

Future applications of GPR183 antibodies in therapeutic research include:

• Biomarker development: Standardized GPR183 detection for stratifying patients in clinical trials for autoimmune diseases, particularly SLE where expression correlates with disease activity .

• Therapeutic response monitoring: Using GPR183 expression changes to track efficacy of experimental therapies targeting the oxysterol-GPR183 axis.

• Novel therapeutic target validation: GPR183 antibodies in blocking studies to validate the receptor as a drug target for conditions characterized by dysregulated immune cell migration.

• Companion diagnostic development: GPR183 expression profiling may identify patients most likely to respond to therapies targeting this pathway.

• In vivo imaging: Development of imaging tracers based on GPR183 antibodies to visualize immune cell trafficking non-invasively.

Research indicates that GPR183 expression levels may serve as a biomarker for the activity of therapeutic combinations containing CD47-targeted therapy in B-cell lymphomas, suggesting broader applications in cancer immunotherapy response prediction .